Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors

@article{Castellano2014ExpertCF,
  title={Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors},
  author={Daniel E. Castellano and Enrique Grande and Juan W. Valle and Jaume Capdevila and Diane L Reidy-Lagunes and Juan Manuel O'Connor and Eric Raymond},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2014},
  volume={75},
  pages={1099-1114}
}
Abstract Neuroendocrine tumors (NETs) are rare tumors that have been increasing in incidence over the last 30 years with no significant changes in survival. As survival of patients with these tumors depends greatly on stage and histology, early diagnosis, classification and staging of tumors in patients in whom NETs are suspected are of great importance. Surgery, either with curative or palliative intent, is the mainstay of treatment for localized NETs. Therapeutic options for this disease… 
An update on the management of pancreatic neuroendocrine tumors
TLDR
The authors reviewed the current treatment of pancreatic neuroendocrine tumors and also discussed the emerging agents and emphasized the need to identify biomarkers.
Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?
TLDR
Increasing evidence supports the application of neoadjuvant protocols in advanced pancreatic neuroendocrine tumors aiming at tumor downsizing, thus rendering curative resection feasible.
Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors
TLDR
Ki67 index and lymph node status are independently associated with recurrence after resection of well-differentiated NF-PNETs in this study.
Sunitinib as Neoadjuvant Treatment of Neuroendocrine Pancreatic Tumors: Case Report
TLDR
A case of 39-year-old women admitted for management of nonfunctioning locally advanced PNET with the invasion of the Superior Mesenteric Vein and duodenum and sunitinib treatment, where the patient has remained recurrent free for 18 months.
A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors
TLDR
This new scoring system could predict recurrence after curative resection of grade 1 and 2 NF-pNET with the use of the recurrence score, and less extensive follow-up could be proposed for patients with low recurrence risk.
Surgical Management of Pancreatic Neuroendocrine Tumors.
Validation of the 8th AJCC Cancer Staging System for Pancreas Neuroendocrine Tumors Using Korean Nationwide Surgery Database
TLDR
The revised 8th AJCC staging system for pancreatic neuroendocrine tumor provides better discrimination compared to that of the 7th edition and ENETS TNM system and supports the clinical use of the system.
Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET)
TLDR
Analysis of GLO1 copy-number variation particularly in patients with midgut NET could be a novel prognostic marker for tumour progression.
PRRT with Radiolabeled Peptides: Indications, Procedures, and Results
Peptide receptor radionuclide therapy (PRRT) is an effective and usually well-tolerated treatment for unresectable or metastatic neuroendocrine tumors expressing somatostatin receptors. The two
...
...

References

SHOWING 1-10 OF 97 REFERENCES
Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
TLDR
Hepatic artery embolization frequently results in clinical and radiographic responses in patients with unresectable liver metastases from carcinoid or pancreatic endocrine tumors andMorbidity is low when appropriate supportive care is provided and major toxicities were rare.
Neuroendocrine gastrointestinal tumors - A condensed overview of diagnosis and treatment
TLDR
The medical treatment of neuroendocrine tumors has made a real break through with the introduction of somatostatin analogues, particularly octreotide, and today most of the hormonally related symptoms can be controlled by this kind of treatment.
Minimally Invasive Techniques in Management of Hepatic Neuroendocrine Metastatic Disease
TLDR
Results and analysis discussed will refer to well-differentiated neuroendocrine tumor lines and Reference will be made to the specific cohort of patients in instances where outcomes are based upon subcategorization of embryologic origin, carcinoid specific lines, and/or associated symptomology.
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms
TLDR
The anaplastic neuroendocrine tumor is strongly responsive to therapy with combined etoposide and cisplatin and should be evaluated for this possibility with appropriate immune staining or electron microscopy.
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.
TLDR
Patients with locally advanced or metastatic PEC who are treated with FAS may have a reasonable RR, and responders may experience longer PFS and OS, and the volume of metastases in the liver is the most important predictor of outcome.
Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors
TLDR
Thalidomide was fairly well tolerated in patients with metastatic carcinoid/islet cell tumors, but failed to reveal any objective responses.
Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors
TLDR
Temozolomide as monotherapy had acceptable toxicity and antitumoral effects in a small series of patients with advanced malignant neuroendocrine tumors and four of these showed radiologic responses.
Hepatic artery embolization for treatment of patients with metastatic carcinoid tumors: a commentary.
TLDR
It is clear that hepatic artery ablation can be tients may be treated with the long-acting depot useful for patients with advanced liver tumor burdens, and advantages of chemobe treated with octreotide when undergoing any invasive embolization over bland emblization are unknown.
A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.
  • J. Strosberg, J. Weber, L. Kvols
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2012
TLDR
Hematic TAE is a highly active treatment option for patients with metastatic NETs to the liver and sunitinib, an oral VEGFR inhibitor, can be safely administered following embolization.
A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.
TLDR
Hematic TAE is a highly active treatment option for patients with metastatic NETs to the liver and sunitinib, an oral VEGFR inhibitor, can be safely administered following embolization.
...
...